Category Archives: Biotechnology

Jon Entine, Executive Director, Genetic Literacy Project,oversaw the assignments and the editing of this series INTRODUCTION: Genetically engineered crops and animals (GMOs) have been a controversial public issue since the first products were introduced in the 1990s. They have posed unique challenges for governments to regulate. Although most working scientists in the field hold the opinion that genetic engineering, for the most part, is part of a continuum of the human manipulation of our food supply thats gone on for thousands of years, critics contend differently. Many crop biotechnology skeptics frame their concerns in quasi-religious terms, as a violation of nature or fears that the increased use of GE foods will lead to a corporate takeover of our seed and food systems, and the adoption of an ecologically destructive industrialized agriculture system. GMOs have become a symbol of the battle over what our global, regional and local food systems should look like going forward. The clout of the food movement that vocally rejects many aspects of conventional farming has exponentially increased since then, promoted by mainstream journalists, scientists and non-profit groups from Michael Pollan to Consumers Union to the Environmental Working Group. Organic leaders and lobbyists, such as Gary Hirshberg, … Continue reading →

Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here. Cellect Biotechnology Ltd. (Nasdaq: APOP), a developer of stem cells selection technology, today announces that it has treated the first blood cancer patient in the recently initiated Phase I/II trial of its stem cell technology ApoGraft. The trial is intended to assess the Cellect ApoGraft process which is designed to prevent Graft-versus-Host Disease (GvHD), a common complication associated with stem cell transplant in which the transplanted immune cells attack the recipient's body cells and organs. GvHD is a life-threatening condition occurring in up to 50% of stem cell transplants. In this trial, the company will be testing stem cells transplanted from a matched donor related to the patient. Referring to the trial on healthy volunteers, the company plans to release definitive and complete results of this trial before the end of Q1 this year. Cellect CEO, Shai Yarkoni commented, Enrolling our first cancer patient to be treated using our groundbreaking method is a critical milestone for millions of patients worldwide. ApoGraft has been proven to be effective in assisting successful stem cells transplants and preventing GvHD during our animal studies. I … Continue reading →

iShares Nasdaq Biotechnology Index Fund (IBB) dropped by -0.35 or -0.98 points during the last session to $282.56 per share. One of the highlights of the day was the net money flow figure, which stood at $2 million even as the stock accepted $4.91 million in upticks but rejected $2.91 million in downticks. The up/down ratio for the last observation was a 1.69. The 1-week percentage change for the stock price is registered at -0.17%.Block trades are executed by Investment Banking firms or Wealth Managers shifting positions or Day traders taking advantage of trading signals. Stock price is down 6.42% since it reached the one year high price and is down $ -19.39 since then. The company shares are up 17.52% from one year low and is up $42.11 since then. The Stock has a 52 week low of $240.3 and one year high of $301.8. iShares Nasdaq Biotechnology Index Fund (NASDAQ:IBB) stock ended Tuesday session in the red zone in a volatile trading. The stock closed down 1.13 points or 0.4% at $282.41 with 1,137,322 shares getting traded. Post opening the session at $284.2, the shares hit an intraday low of $280.87 and an intraday high of $284.48 and … Continue reading →

Commentary | Feb. 6, 2017 Should Christians face unethical uses of biotechnology with despair and resignation or with hope and determination? Ive spent the last decade writing and speaking about the remarkable and terrifying world of biotechnology from a Catholic perspective. Many times Ive felt like Frodo Baggins at the gates of Mordor, looking upon Mt. Doom with despair and dread. Ive never felt this more acutely than in the past few months. A series of recent headlines have renewed my sense of hopelessness in the face of the never-ending assault on the dignity of human life by modern biotechnology. The gloom began to settle when it was revealed that a Swedish scientist is editing the DNA of healthy human embryos.Fredrik Lanner,a developmental biologist, is using a new gene-editing technique called CRISPR to disable some genes in healthy human embryos to see how those genes affect development. He and his team are intentionally modifyingotherwise healthy IVFembryos so they cannot develop properly. Anin-depth story byNPRreveals that while the reporter was observing thegeneticmanipulation of five donated IVF embryos, one didnt survive the thawing process and one perished after being injected with the experimental gene-editing tool. Of the three who survived, one continued … Continue reading →

President Trump pressed Big Pharma executives to increase U.S. production and lower drug prices. As biotechnology stocks have been showing momentum following a meeting between President Trump and pharmaceutical executives Tuesday, our two long investments to watch are in that sector. There are also several shorts among our charts to watch to play the potential downside in this near-term, toppy-looking stock market. Gene-therapy company bluebird bio Inc. BLUE, -2.10% has a strong-looking chart. The stock recently broke out of a wedge pattern, in which its price range had narrowed for two months in essentially a sideways direction. The stock continued the upmove on Tuesday when it popped $5.90, or over 8%, to $74.50, and followed through for another $1.10 on Wednesday to $75.60. The stock is now positioned to challenge its recent high at $79.70 from early December. A break through there could lead to a move into the mid-$80s, followed by a next target in the mid-$90s. With short interest of 9.2 its average volume, the price advance could be further fueled by short covering. Cara Therapeutics Inc. CARA, +0.12% a cannabis-based biotech, has been steadily climbing since the start of the year. On Wednesday, the stock popped $1.17, … Continue reading →

Bioverativ Inc. (BIVV) ended last trading session with a change of 3.76 percent. It trades at an average volume of 13.38M shares versus 3.28M shares recorded at the end of last trading session. The share price of $44.44 is at a distance of 4.81 percent from its 52-week low and down -4.22 percent versus its peak. The company has a market cap of $4.86B and currently has 109.41M shares outstanding. The share price is currently 0.85 percent versus its SMA20, 0.85 percent versus its SMA50, and 0.85 percent versus its SMA200. The stock has a weekly performance of 0 percent and is -1.2 percent year-to-date as of the recent close. Bioverativ Inc. (BIVV) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively. Novavax, Inc. (NVAX) recently recorded -1.5 percent change and currently at $1.31 is 12.93 percent away from its 52-week low and down -84.57 percent versus … Continue reading →

Insider Selling: Puma Biotechnology Inc (PBYI) Insider Sells ... Sports Perspectives Puma Biotechnology Inc (NYSE:PBYI) insider Robert Charnas sold 3008 shares of the firm's stock in a transaction that occurred on Wednesday, February 1st. The Puma Biotechnology Inc (PBYI) Insider Sells $95744.64 in StockDailyQuint Robert Charnas Sells 3008 Shares of Puma Biotechnology Inc (PBYI) StockCommunity Financial News all 8 news articles » Read the original: Insider Selling: Puma Biotechnology Inc (PBYI) Insider Sells ... - Sports Perspectives … Continue reading →

Biotechnology has proven to be an important tool for better sustainability and food security. It helps farmers grow more food while improving the environment. For example, biotechnology reduces the use of costly inputs and improves weed management, allowing farmers to reduce tillage for better soil, water and air quality. Today, roughly 90 percent of corn, cotton and soybeans grown in the U.S. have been improved through biotechnology, and farmers are choosing biotech traits when growing other crops such as alfalfa, sugarbeets and canola. Despite rapid adoption by farmers and a strong scientific consensus that biotechnology does not pose health and environmental risks, regulatory burdens are slowing research and innovation of new biotech traits and are starting to reduce U.S. farmers international competitive advantage. In addition, activist groups routinely threaten the availability of new traits by blocking science-based regulatory decisions, filing lawsuits and advocating for labeling mandates. GM crops require less water and fewer chemical applications than conventional crops, and they are better able to survive drought, weeds, and insects. U.S. agriculture will maintain its competitive advantage in world markets only if we continue to support innovations in technology and grasp opportunities for future biotech products. To improve regulation of biotechnology, … Continue reading →

3 Biotech is a quarterly, peer-reviewed open access journal published under the brand SpringerOpen. Continuous Article Publishing (CAP) 3 Biotech will be moving to the Continuous Article Publishing (CAP) in 2016, in which newly accepted papers will be published online with volume and article numbers, shortly after receipt of authors proofs. This change will alleviate the significant backlog of accepted articles that are currently available online as "published ahead of time," but are awaiting formal publication with a volume, issue number and page numbers. To achieve a smooth transition to the CAP model, all papers that have been accepted after June 2015 have been held back and will be published with volume and article numbers from January 2016 onwards. We wish to apologize for this short delay in article processing during this important transition phase, which is designed to speed up the process from acceptance of articles to final publication without the need for articles to be placed in a "published ahead of time" waiting line. In addition, a formal rapid publication from 2016 will ensure that all articles in 3 Biotech are immediately available in indexing services for researchers. 3 Biotech publishes the results of the latest research related … Continue reading →

Journal of Biotechnology & Biomaterials is a peer reviewed journal which publishes high quality articles reporting original research, review, commentary, opinion, rapid communication, case report etc. on all aspects of Biotechnology and Biomaterials. Content areas include Plant/Animal/Microbial Biotechnology, Applied Biotechnology, Red/Medical Biotechnology, Green/Agricultural Biotechnology, Environmental Biotechnology, Blue/Marine Biotechnology, White/Industrial Biotechnology, Food Biotechnology, Orthopedic and Dental Biomaterials, Cardiovascular Biomaterials, Ophthalmologic Biomaterials, Bioelectrodes and Biosensors, Burn Dressings and Skin Substitutes, Sutures, Drug Delivery Systems etc. This Biotechnology Journal with highest impact factor offers Open Access option to meet the needs of authors and maximize article visibility. The journal is an academic journal providing an opportunity to researchers and scientists to explore the advanced and latest research developments in the use of living organisms and bioprocesses in engineering, technology and medicine. The Journal of Biotechnology and Biomaterials is of highest standards in terms of quality and provides a collaborative open access platform to the scientists throughout the world in the field of Biotechnology and Biomaterials. Journal of Biotechnology and Biomaterials is a scholarly Open Access journal and aims to publish the most complete and reliable source of information on the advanced and very latest research topics. The journal is using the Editorial Manager … Continue reading →